Breast Cancer Biomarkers

M.Haugen
M.Haugen

PI: Mads H. Haugen

Breast cancer remains a leading cause of death and suffering in a global perspective, despite the impressive advances in treatment options. Additionally, the rate of new drugs actually being approved and used in the clinic is disturbingly low. There is thus a need to focus on optimization of both novel and available treatments, so these can be of benefit to cancer patients. In our ongoing projects of identifying biomarkers we focus on development of novel procedures and strategies to classify which breast cancer patients respond to selected treatments.   Molecular precision medicine in breast cancer

 

 

 
Page visits: 330